

**AMENDMENT TO RULES COMM. PRINT 119-8**  
**OFFERED BY MRS. BIGGS OF SOUTH CAROLINA**

Page 792, before line 8, insert the following new section (and redesignate accordingly):

**1 SEC. 13\_\_\_\_. COUNTERING BIOTECHNOLOGY THREATS**  
**2 FROM THE PEOPLE'S REPUBLIC OF CHINA.**

**3 (a) SENSE OF CONGRESS.—**It is the sense of Congress that—

**5 (1)** the rapid advancement of the People's Republic of China in biotechnology, including gene-editing, synthetic biology, and dual-use technologies, poses a significant threat to the national security of the United States and its military superiority;

**10 (2)** China's military-civil fusion strategy integrates civilian biotechnology research with military applications, potentially enabling the development of enhanced soldier capabilities, bioweapons, and other asymmetric threats;

**15 (3)** China's dominance in global biotechnology supply chains and its strategic investments in United States biotechnology firms risk undermining United States innovation, security, and access to critical resources;

1 (4) the United States must proactively integrate  
2 biotechnology threats into its defense planning and  
3 intelligence assessments to maintain strategic advan-  
4 tages; and

5 (5) robust oversight of foreign investments and  
6 partnerships in the United States biotechnology sec-  
7 tor is essential to safeguard sensitive technologies  
8 and data from adversarial exploitation.

9 (b) INTEGRATION OF THREATS INTO NATIONAL DE-  
10 FENSE STRATEGY.—Chapter 2 of title 10, United States  
11 Code, is amended by adding at the end the following new  
12 section:

13 **“§ 118d. Integration of Biotechnology Threats into**  
14 **National Defense Strategy and Defense**  
15 **Planning Guidance.**

16 “(a) The Secretary of Defense shall develop a strat-  
17 egy to ensure that threats posed by the biotechnology ca-  
18 pabilities of foreign adversaries, particularly the People’s  
19 Republic of China, are integrated into—

20 “(1) the National Defense Strategy; and

21 “(2) the Defense Planning Guidance.

22 “(b) The strategy required under subsection (a) shall  
23 include—

24 “(1) an assessment of foreign adversaries’ use  
25 of military and dual-use biotechnology for military

1 purposes, development of biological agents, and abil-  
2 ity to disrupt international and United States supply  
3 chains critical to military operations;

4 “(2) strategies to counter such threats, includ-  
5 ing investments in U.S. biotechnology research and  
6 development, supply chain resilience, and defensive  
7 biotechnological capabilities; and

8 “(3) coordination with allies and international  
9 partners to address biotechnology-related national  
10 security risks.

11 “(c) The Secretary of Defense shall develop the strat-  
12 egy required by this section in consultation with the Sec-  
13 retary of State, the Secretary of Health and Human Serv-  
14 ices, the Secretary of Homeland Security, the Director of  
15 National Intelligence, defense and technology industry  
16 partners, research and development partners, other Fed-  
17 eral research agencies, allies and partners of the United  
18 States, and other appropriate organizations.

19 “(d)(1) The Secretary of Defense shall submit to the  
20 appropriate congressional committees a report, in unclas-  
21 sified form but which may contain a classified annex, that  
22 includes the strategy developed pursuant to subsection (a).

23 “(2) In this subsection, the term ‘appropriate con-  
24 gressional committees’ means—

1           “(A) the Committee on Armed Services, the  
2           Committee on Foreign Relations, the Committee on  
3           Commerce, Science, and Transportation, and the  
4           Committee on Banking, Housing, and Urban Affairs  
5           of the Senate; and

6           “(B) the Committee on Armed Services, the  
7           Committee on Foreign Affairs, the Committee on  
8           Energy and Commerce, and the Committee on Fi-  
9           nancial Services of the House of Representatives.”.

10          (c) ASSESSMENT OF CHINA’S USE OF BIO-  
11          TECHNOLOGY FOR MILITARY MODERNIZATION.—

12           (1) IN GENERAL.—Not later than 180 days  
13           after the date of the enactment of this Act, the Di-  
14           rector of National Intelligence, in consultation with  
15           the Director of the Central Intelligence Agency, the  
16           Secretary of Commerce, and the Secretary of De-  
17           fense, shall submit to the appropriate congressional  
18           committees a comprehensive assessment of the Peo-  
19           ple’s Republic of China’s use of biotechnology for  
20           military modernization.

21           (2) ELEMENTS OF ASSESSMENT.—The assess-  
22           ment required under paragraph (1) shall include—

23                   (A) an evaluation of China’s biotechnology  
24                   research and development programs with poten-

1            tial military applications, including gene-edit-  
2            ing, synthetic biology, and bioinformatics;

3            (B) an analysis of China's military-civil fu-  
4            sion strategy and its impact on advancing mili-  
5            tary biotechnology capabilities;

6            (C) an assessment of the potential for  
7            China to develop biological weapons or other  
8            asymmetric biotechnological threats;

9            (D) an assessment of Chinese entities, in-  
10           including private companies, state-owned enter-  
11           prises, and government bodies, that are devel-  
12           oping dual-use biotechnology and any depend-  
13           encies they have on United States or other for-  
14           eign technology, components, or services;

15           (E) an evaluation of China's control over  
16           global biotechnology supply chains and the im-  
17           plications for United States military readiness;  
18           and

19           (F) recommendations for countermeasures,  
20           including enhanced intelligence collection, ex-  
21           port controls, and international cooperation.

22           (3) FORM.—The assessment shall be submitted  
23           in an unclassified form, and may contain a classified  
24           annex.

1 (d) INTERAGENCY COORDINATION ON BIO-  
2 TECHNOLOGY RISK.—

3 (1) IN GENERAL.—Not later than 180 days  
4 after the date of the enactment of this Act, the Sec-  
5 retary of Defense, in consultation with the Secretary  
6 of State, the Secretary of Commerce, the Secretary  
7 of the Treasury, and other appropriate Federal  
8 agencies, shall establish monitoring and evaluation  
9 mechanisms to conduct risk assessments by con-  
10 vening a Biotechnology Risk Contact Group to carry  
11 out the duties described in paragraph (2).

12 (2) BIOTECHNOLOGY RISK CONTACT GROUP.—  
13 The Biotechnology Risk Assessment Contact Group  
14 convened pursuant to paragraph (1) shall—

15 (A) monitor and assess foreign invest-  
16 ments, partnerships, and joint ventures in the  
17 United States biotechnology sector, with a focus  
18 on investments by entities from the People's  
19 Republic of China;

20 (B) identify risks to national security  
21 posed by such investments, including the poten-  
22 tial transfer of sensitive technologies, intellec-  
23 tual property, or genomic data;

1 (C) coordinate with the Committee on For-  
2 eign Investment in the United States to review  
3 biotechnology-related transactions;

4 (D) develop and maintain a database of  
5 foreign entities involved in the United States  
6 biotechnology sector, including their affiliations  
7 with foreign governments or military organiza-  
8 tions; and

9 (E) provide annual reports to Congress on  
10 foreign activities in the United States bio-  
11 technology sector, along with recommendations  
12 for mitigation measures.

13 (3) BRIEFING.—Not later than 180 days after  
14 the establishment of the Biotechnology Risk Contact  
15 Group, and every 90 days thereafter, the Secretary  
16 of Defense, in consultation with the Secretary of  
17 State, the Secretary of Commerce, and the Secretary  
18 of the Treasury, shall brief the appropriate congres-  
19 sional committees on the activities of the Group.

20 (e) APPROPRIATE CONGRESSIONAL COMMITTEES DE-  
21 FINED.—In this section, the term “appropriate congres-  
22 sional committees” means—

23 (1) the Committee on Armed Services, the  
24 Committee on Foreign Relations, the Committee on  
25 Commerce, Science, and Transportation, and the

1       Committee on Banking, Housing, and Urban Affairs  
2       of the Senate; and  
3           (2) the Committee on Armed Services, the  
4       Committee on Foreign Affairs, the Committee on  
5       Energy and Commerce, and the Committee on Fi-  
6       nancial Services of the House of Representatives.

